Year: 2025
Type: article
Abstract: Weekly doses of the glucagon‐like peptide 1 (GLP‐1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9‐week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in JAMA Psychiatry.
DOI: 10.1002/pu.31307
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4409944728